FLOVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
FLOVENT by GSK is anti-inflammatory activity. First approved in 1996.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOVENT (fluticasone propionate) is an inhaled corticosteroid approved in 1996 for asthma treatment. It works by reducing inflammation in the airways through high-affinity glucocorticoid receptor binding (18× dexamethasone) with minimal systemic bioavailability (<1%). The drug exhibits a favorable topical-to-systemic activity ratio, making it suitable for chronic maintenance therapy.
LOE Approaching
FLOVENT faces moderate competitive pressure (score: 30/100) in a crowded inhaled corticosteroid market with approaching loss of exclusivity, likely driving defensive positioning and cost-management strategies.
Mechanism of Action
anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.